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Abstract
Background Home parenteral nutrition (HPN) is a life-
saving therapy for patients with diseases that preclude
adequate oral or enteral food intake. HPN has a large
impact on daily life. Many patients suffer from fatigue and
depression, and they experience limits in social activities.
This all contributes to a lower quality of life.
Purpose Fatigue is the most frequently mentioned problem
in Dutch HPN patients. Therefore, we studied the preva-
lence, course and predictors of fatigue in these patients.
Methods Patients completed questionnaires at baseline and
follow-up (12 months later). Measurements included
fatigue, depression, functional impairment, social support,
self-efficacy, coping, anxiety and acceptance. Laboratory
measures, including total bilirubin, creatinine, albumin and
haemoglobin levels, were obtained from the medical
records. Descriptive statistics, correlations and linear
regression analysis were performed.
Results The response rate was 71% (n=75). Sixty-five per
cent of the patients were severely fatigued (n=49). Eighty-
nine per cent experienced persistent fatigue. Baseline
fatigue predicted 57% of the variance of fatigue at follow-
up, and avoidance was responsible for 3% of the variance.
No significant correlations between fatigue and laboratory
measures were found. A cross-sectional analysis showed
that 46% of the variance of fatigue was explained by
functional impairment, self-efficacy and depression.
Conclusion Severe fatigue is a persistent problem for HPN
patients. Baseline fatigue was the strongest predictor of
fatigue at follow-up. Functional impairment, self-efficacy
and depression are strongly related to fatigue. Early
recognition and treatment of fatigue are important.
Keywords Home parenteral nutrition.Fatigue.Functional
impairment.Self-efficacy.Depression
Introduction
Home parenteral nutrition (HPN) has been used for the
management of intestinal failure since the late 60s of the
previous century. This treatment modality is life-saving for
patients with an inadequate oral or enteral food intake of
nutrients and fluids. Most patients suffer from intestinal
failure due to short bowel syndrome or motility disorders
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DOI 10.1007/s12529-010-9116-7[1]. HPN is used alone or in conjunction with oral feeds. The
support of patients on HPN requires a dedicated multidisci-
plinary team. This team should be available for instructions to
patients, advice and treatment of complications on a 24/7
basis. During their training period, patients who are fit to
perform HPN administration become knowledgeable and
skilled in the performance of aseptic techniques, catheter care
and the intravenous administration of nutrients. Also, these
patients are trained to contact their treatment centre in case of
suspected catheter infection, occlusion or other problems of
the therapy [2].
Several studies describe that HPN is associated with
medical complications [3, 4]. These complications may be
related to the central venous catheter or to the nutrition
formula [5]. However, HPN also has a major impact on
daily life, and many patients suffer from fatigue and
depression [6–10]. Not unexpectedly, HPN also limits
social activities and impairs quality of life [8, 9].
A Dutch study showed that fatigue is the foremost and
most frequently mentioned problem in HPN patients. Sixty
per cent of the HPN patients were severely fatigued, and
fatigue was reported by 90% of these patients as a main
problem in daily life (n=43) [9]. It was found that HPN
patients were more fatigued when compared with patients
suffering from functional bowel disorder or cerebrovas-
cular accident, and fatigue scores corresponded with
those seen in patients with multiple sclerosis. More
specifically, a higher level of fatigue was related to the
presence of passive coping strategies and believing that
good health is determined by fate. Depressive symptoms
were present in 65% of 48 HPN patients, 17% of whom
experienced severe depressive symptoms [9]. Social
impairment also was a commonly reported problem.
Almost half of the respondents mentioned social limita-
tions as a problem in daily life. Increased social impair-
ment was strongly related to a lower quality of life. Social
impairment was more often reported when compared to
patients on haemodialysis, cancer patients and patients
suffering from rheumatoid arthritis [11].
Fatigue is a common symptom in various chronic
diseases. It has mostly been studied in patients with chronic
fatigue syndrome, cancer, multiple sclerosis, Parkinson’s
disease, renal disease and after stroke [12–17]. Physical as
well as psychosocial predictors have been reported in the
literature. Vercoulen et al. [16] found that 85% of multiple
sclerosis patients and 100% of chronic fatigue syndrome
(CFS) patients felt fatigued at least once a week as
compared to only 13% of the healthy individuals. Several
studies show that persistent fatigue is predicted by the
presence of fatigue at the baseline measurement [18–20].
Vercoulen et al. [16, 21] developed a multidimensional
assessment method for CFS and other chronic disorders.
Nine relatively independent dimensions of CFS were
identified, namely psychological well-being, functional
impairment in daily life, sleep disturbance, concentration
problems, physical activity, social functioning, social
support, causal attributions and self-efficacy.
In CFS patients, fatigue severity was related to impair-
ment in daily life and low sense of control. Other predictors
of fatigue in chronic diseases are depression and anxiety
[15, 22, 23], psychological well-being, high impairment in
role functioning, disability, acceptance, self-efficacy and
problematic social support [23–25].
Besides psychosocial factors, physiological factors may
be related to fatigue. For example, McCann and Boore [12]
found that malnutrition causes fatigue in renal failure
patients. Srivastava [26] and Piper et al. [27] found that
anaemia affects the reported levels of fatigue. Other studies,
however, did not find these associations [12, 28–31].
So far, longitudinal studies regarding fatigue in patients on
long-term HPN are lacking. The current study presents the
longitudinal data of a cohort of HPN patients during a 12-
month period. Based on the literature in other chronic patient
groups, fatigue in HPN patients might be predicted by the
presence or absence of disease activity, depression, self-
efficacy, coping, acceptance, anxiety, functional impairment
and social support. The aims of this study were (1) to describe
the prevalence and course of fatigue and (2) to evaluate
baseline fatigue and the aforementioned set of psychosocial
and physiological factors in the prediction of fatigue.
Method
Patients
All 106 HPN patients treated at the Radboud University
Nijmegen Medical Centre or the Academic Medical Centre
in Amsterdam at the start of the study in October 2007 were
asked to participate in this study. These patients represent
about 90% of all patients receiving long-term HPN in the
Netherlands. Patients had to be on HPN for at least
3 months at T1. We excluded patients younger than
18 years. The regional committee on Research Involving
Human Subjects waived the need for a review of the study
because we used questionnaires and medical records only.
Patients received a written invitation to participate.
Procedure
After obtaining a written informed consent, questionnaires
were sent to the patients (baseline). Participants were asked to
completethequestionnaireswithin2weeksandtoreturnthem
in a prepaid envelop. After 1 year, a part of the questionnaire
was sent again by mail (follow-up), measuring general and
HPN-related characteristics, and fatigue. In case of missing
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questionnaires.PatientswhohaddiscontinuedHPNatfollow-
up were still asked to fill out a questionnaire. Results for these
patientswereanalysedseparately.Laboratorymeasures(taken
duringregularcheckupsattheoutpatientclinic)wereobtained
from the medical records at T1 and T2.
Measurements
The questionnaire addressed general and HPN-related
characteristics.
Fatigue
The subscale ‘Fatigue Severity’ from the Checklist Indi-
vidual Strength (CIS) is an eight-item questionnaire and
measures fatigue during the previous 2 weeks [32]. Each
item was scored on a seven-point Likert scale. High scores
indicate a high level of experienced fatigue. Severe fatigue
was defined as a CIS fatigue score equal to or higher than
35 [21]. A score between 27 and 34 indicates high
experience of fatigue. In this study, a score of 35 or above
at baseline as well as at follow-up was seen as indicating
‘persistent severe fatigue’. The CIS has been tested
thoroughly among patients with different chronic diseases
and healthy controls [16, 21, 32]. The internal consistency
of the CIS is good: Cronbach’s α for the total CIS was 0.90
and was 0.88 for the subscale ‘fatigue severity’. Convergent
validity was previously reported to be satisfactory [33].
Depression
The Beck Depression Inventory for Primary Care (BDI-PC)
was used to assess depression. The BDI-PC does not
contain questions concerning physical aspects of fatigue or
somatic symptoms of depression [34, 35]. The BDI-PC has
seven items and consists of cognitive and affective
symptoms. Each item is rated on a four-point scale ranging
from 0 to 3. A score of 4 or more indicates clinical
depression. This score was found to correctly classify
patients as being diagnosed with or without major depres-
sive disorders (MDD) according to DSM-IV. The internal
consistency is high (α=0.86). With regard to the conver-
gent validity, the BDI-PC was positively associated with the
diagnosis of MDD (r=0.66, p<0.001) [35].
Functional Impairment
The Sickness Impact Profile short form 68 (SIP-68) was
included in our study as it is a widely used measure of the
impact of disease on an individual’s physical and psycho-
social functioning [36]. Patients are required to read
through a list of conceivable difficulties and to identify
which of these apply to them using a yes/no response
format. Scores range between 0 and 68, with a higher score
indicating more functional impairment. The internal con-
sistency is high; Cronbach’s α=0.92 [36, 37].
Social Support
The Van Sonderen Social Support Inventory (SSL) was
used to assess social support [38]. Total scores of the SSL-I
(number of social interactions) range from 34 to 136, a
higher score meaning more social support. Subscales are
emotional interactions, emotional support problems, esteem
support, instrumental interactions, social companionship
and informational support. The SSL has good reliability
(Cronbach’s α=0.93 for SSL-I) and content validity [39].
Self-Efficacy
Self-efficacy, a sense of control over fatigue symptoms, was
measured with a Self-Efficacy Fatigue Questionnaire.
Seven items measured sense of control with respect to
fatigue. Total scores range from 7 to 28, a higher score
meaning a patient experiences more control with respect to
fatigue [17]. Cronbach’s α reliability coefficients range
from 0.70 to 0.77 [18, 40].
Coping
The subscales avoidance and problem-focused coping of
the UCL (Utrechtse Coping List) were used to assess
coping [41]. A high score on a subscale means that the
individual uses that coping style often. The internal
consistency is moderate to high (α=0.66 for avoidance,
α=0.78 for problem focused coping) [42].
Anxiety
In a previous study [7], the State-Trait Anxiety Inventory
[43, 44] was not sensitive enough to measure specific
anxiety in HPN patients. Therefore, a specific questionnaire
was used to measure anxiety. Based on interviews in a 2003
study, six questions specific for anxiety in HPN patients
were developed. These items were scored on a four-point
scale (‘not at all’ to ‘almost always’). Total scores ranged
from 6 to 24, a higher score meaning a patient experiences
more anxiety with respect to HPN complications or
hospitalisations, future or even death.
Acceptance
Acceptance was measured with a subscale of the Illness
CognitionQuestionnaire.Thisquestionnaire measuresdifferent
patient cognitions about chronic illness and giving meaning in
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to 4, completely), a higher score meaning better acceptance.
The reliability (Cronbach’sα=0.90, test–retest reliability 0.76)
and validity of acceptance were found to be high [45].
Laboratory Measures
Relevant laboratory measures were obtained from the
medical records. We evaluated liver function (total biliru-
bin), renal function (creatinine), inflammation (albumin)
and haemoglobin levels.
Statistical Analysis
Data analyses were performed using SPSS for Windows
version 16.0. Variables were distributed normally, and
therefore, parametric tests were performed. Descriptive
statistics such as mean, standard deviation and range were
used to describe the participants and to evaluate laboratory
measurement outcomes. Paired-sample t tests were per-
formed to analyse differences between baseline and follow-
up scores. Values of p<0.05 were considered statistically
significant.
Associations between potential predictive variables at
baseline and fatigue at follow-up were examined by
calculating the Pearson’s correlation coefficient. Pearson’s
correlation coefficient was also used to analyse relations
between the predictive variables at baseline and to identify
possible multicollinearity.
We performed a longitudinal linear regression analysis in
which we entered variables which were possibly connected to
fatigue at follow-up as independent variables and fatigue at
follow-up as dependent variable (model 1). Subsequently, we
performed a cross-sectional backward stepwise linear regres-
sion analysis with fatigue at baseline as dependent variable
and potential predictive variables for fatigue from baseline as
independent variables (model 2). This second model was
added because we knew from literature that persistent fatigue
could be predicted by the presence offatigue at baseline alone
[23]. Therefore, model 2 might give information on the
relative importance of other important variables explaining
fatigue. Predictive variables were removed from the model
when they met the removal criterion of p>0.05.
Results
Patient Characteristics
The response rate at baseline was 71% (i.e. 75 out of 106
patients). No differences in gender, age, duration of HPN
therapy or the indication for HPN were found between
respondents and patients who refused to participate. At
follow-up, 68 out of 75 patients were able to fill out the
questionnaire again (Fig. 1). Eight patients discontinued
HPN, but filled out the questionnaire at follow-up. The
reason for discontinuing HPN was being able to eat
sufficiently again due to adaptation of the remaining small
intestinal mucosa in all patients. All follow-up analyses
pertain to the 60 patients still on HPN. The eight patients
who discontinued HPN were analysed separately.
Questionnaires that were completed by patients were
checked, and in case of missing data, patients were
contacted to complete the questionnaires. As no missing
values occurred, all 60 cases were included in the analysis.
At baseline, patients’ median age was 56 (range 19–81),
63% were women, 80% were married or cohabiting, and
merely 20% was employed. Indications for HPN were short
bowel syndrome, mostly related to inflammatory bowel
disease or mesenteric thrombosis (n=41, 55%) and motility
disorders (n=34, 45%; Table 1). Patients were on HPN for
median 2 years (range 3 months to 30 years). Almost 75%
was able to use solid or liquid food to some extent.
106 patients invited
75 patients included
at baseline
7 patients died
between baseline
and follow up
8 patients
discontinued HPN 
(regained enteral
autonomy)
60 patients still on 
HPN
68 patients
included at follow
up
31 patients did not
participate
Fig. 1 Patient flowchart
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were in accordance with the reference ranges (Table 1) and
therefore did not indicate the occurrence of fatigue in the
patient population. These laboratory measures were not
included in our analysis because they did not correlate
significantly with fatigue.
Prevalence and Course of Fatigue
The baseline fatigue score was 37.9±13.6 (mean, SD), and
62% of all patients scored 35 or higher. At follow-up, the
mean fatigue score was 38.8±13.2 (difference 0.9, p=0.45);
63% of the patients scored 35 or higher. The correlation
between baseline and follow-up CIS fatigue scores was
0.75 (p<0.001). Eighty-nine per cent of the patients who
were identified as severely fatigued at baseline were
severely fatigued at follow-up as well (Table 2).
Patients who discontinued HPN at follow-up (n=8)
had a mean age of 44±12 (median 47); five of them were
women, five were married or cohabiting, and five of them
were employed. They showed a mean fatigue score of
43.1±10.0 at follow-up. This did not differ from their
baseline fatigue score (mean 43.8±10.3, p=<0.001). Five
of these were identified as severely fatigued at both
baseline and follow-up.
Predictors of Fatigue
The correlations between the predictive variables and fatigue
at follow-up are presented in Table 3. We found multi-
collinearity between depression and acceptance (r=−0.651)
and between depression and anxiety (r=0.628). Based on
these results, acceptance and anxiety were excluded, and
avoidance, social companionship, functional impairment,
self-efficacy and depression were included in the regression
analysis.
The longitudinal analysis with fatigue at follow-up as
dependent variable and fatigue, depression, self-efficacy,
avoidance, functional impairment and social companion-
ship at baseline as independent variables showed that 60%
of the variance in fatigue was predicted by fatigue and
avoidance. Fatigue was responsible for 57%, and avoidance
was responsible for 3% of the variance (Table 4, model 1).
Cross-sectionally, the analysis with baseline fatigue as
dependent variable and depression, self-efficacy, avoidance,
functional impairment and social companionship at baseline
N=75
Mean age (years) 53.1 (SD 12.8)
Women, N 47 (63%)
Indication of HPN: short bowel syndrome (versus motility disorders) 41 (55%)
Years on HPN 5.0 (SD 6.2)
T1 T2
Haemoglobin Mean (SD) 7.4 7.4
Percentiles 25–75 7.1–8.0 7.0–7.9
Albumin Mean (SD) 35.8 (4.9) 36.9 (4.9)
Percentiles 25–75 36.5–41.0 34.0–40.0
Total bilirubin Mean (SD) 10.5 (10.9) 8.6 (6.7)
Percentiles 25–75 5.0–12.0 4.0–12.0
Creatinine Mean (SD) 77.8 85.2
Percentiles 25–75 58.8–87.0 62.0–91.5
Table 1 Patient characteristics
Reference ranges (from included
hospitals): haemoglobin 7.5–
10.0, albumin 35–50, total bili-
rubin <17, creatinine 65–95
Table 2 Course of fatigue
T1 T2
Severe fatigue at follow-up Heightened fatigue at follow-up No fatigue at follow-up
Severe fatigue at baseline (n=37) 33 (89%) 2 (5.5%) 2 (5.5%)
Heightened fatigue at baseline (n=8) 3 (37.5) 2 (25) 3 (37.5)
No fatigue at baseline (n=15) 2 (13.3) 5 (33.3) 8 (53.3)
The course of fatigue: numbers and percentages of patients that were classified as severely, heightened or not fatigued at follow-up on the basis of
their classification as severely, heightened or not fatigued at baseline
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explained by functional impairment, self-efficacy and
depression. Functional impairment was responsible for
31% of the variance, self-efficacy for 11%, and depression
was responsible for 4% (Table 4, model 2).
Discussion
We found that severe fatigue is a persistent problem in the
daily life of HPN patients. This finding has also been
reported in other patient categories, such as (disease-free)
breast cancer patients [23], chronic peritoneal dialysis
patients [13] and patients suffering from rheumatoid
arthritis [24]. For HPN patients, no predictors of fatigue
were available from the literature. Our first longitudinal
analysis showed that fatigue is the most important predictor
for persistent fatigue. This result has also been found by
Servaes et al. [23] in disease-free breast cancer patients.
Avoidance was the second predictor of fatigue in HPN
patients. From literature in CFS patients, it is known that
patients avoid all kinds of activities because of the fear that
activity enhances symptoms [46]. Because the body gets
unused to activity, symptoms will emerge at increasingly
lower levels of activity. In this way, a self-fulfilling
prophecy is established. Motivating patients and decreasing
the fear of activity therefore is important to decrease levels
of fatigue. Our second cross-sectional analysis showed that
functional impairment, self-efficacy and depression explain
a considerable part of fatigue at baseline.
WhilstfatigueisafrequentsymptominHPNpatients,ithas
received no attention in research. As HPN patients may suffer
from anaemia, problems with fluid intake/diarrhoea, renal
disease or liver disease, it is reasonable to assume that fatigue
is related to somatic problems. However, our results show no
correlationsbetweenrelevantlaboratorymeasuresandfatigue.
This is in accordance with several studies in patients on
haemodialysis and in patients with primary biliary cirrhosis
where no association was found between anaemia, albumin,
creatinine and bilirubin levels and fatigue [12, 28–31].
As in our study, studies in patients suffering from
rheumatoid arthritis show that the relationships between
psychosocial variables and fatigue are often much stronger
than ‘objective’ measures of disease severity or inflamma-
tory markers, like laboratory values, swollen joints or
deformities [47–49]. Riemsma et al. [50] showed that
laboratory measurements like haemoglobin concentration
and erythrocyte sedimentation rate are not significantly
related to fatigue, whilst psychosocial aspects like self-
efficacy and problematic social support are the most
important variables in explaining fatigue.
With regard to the results for functional impairment, it can
be concluded that HPN patients experiencing more functional
impairment have higher levels of fatigue. Regarding self-
efficacy, a lower sense of control with respect to fatigue
complaints is associated with an increase in experienced
fatigue. Both these findings are consistent with results of
studies in chronic fatigue syndrome patients, multiple sclerosis
patientsandpatientswithrheumatoidarthritis[17, 50]. In these
patient populations, a low self-efficacy was found to have a
direct negative causal effect on fatigue severity. It is known
that self-efficacy can be enhanced by self-management
courses, and it may thus be possible to improve fatigue
[50]. Self-efficacy is also an important aspect of cognitive
behaviour therapy in CFS patients. Prins et al. [40] found that
patients with a greater sense of control at baseline had a larger
decrease in fatigue severity after cognitive behaviour therapy
(CBT) than patients with lower sense of control.
For CFS patients, CBT has been proven to be successful
in reducing fatigue complaints [40, 51–53]. Besides
reducing fatigue severity, CBT also had a positive effect
on functional impairment [40]. A systematic review of Neill
et al. [54] showed the effectiveness of non-pharmacological
interventions for fatigue in chronic diseases. Exercise
Table 3 Pearson correlations between possible continuous predictors
at baseline and fatigue at follow-up
Fatigue
Coping
Active problem solving −0.098
Avoidance 0.330**
Health cognitions
Acceptance −0.369**
SSL-I (amount of social interactions)
Total −0.157
Emotional interactions −0.214
Emotional support problems −0.022
Esteem support −0.185
Instrumental interactions 0.048
Social companionship −0.257*
Informational support −0.166
SSL-N (negative interactions) 0.230
SIP—Total 0.511**
Self-efficacy fatigue −0.443**
Anxiety 0.369**
BDI-PC 0.444**
CIS—Fatigue 0.745**
Laboratory measures
Haemoglobin 0.086
Albumin −0.139
Total bilirubin −0.242
Creatinine −0.036
*p=<0.05; **p=<0.01
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pharmacological intervention for reducing fatigue in people
with multiple sclerosis (MS), rheumatoid arthritis (RA), and
systemic lupus erythematosus (SLE). This is consistent
with recommendations for patients with cancer-related
fatigue and chronic fatigue syndrome. In addition, a range
of behavioural interventions, like energy conservation, may
be helpful in reducing fatigue in MS, RA and SLE [55–57].
Educational interventions also produced statistically signif-
icant reductions in fatigue.
The finding that depression partly explains fatigue is also
confirmed by other studies on fatigue. Leserman et al. [58]
showed that depression directly results in fatigue. Lui [22]
found that depression was the most important predictor of
fatigue in haemodialysis patients. Although this remains to
be proven in future research, in our opinion, the adequate
identification and treatment for depression might also prove
to be an effective strategy for decreasing levels of fatigue
[22, 59]. In HPN patients, a study by Smith et al. [60]
showed that by means of interactive education, depressive
reactions can be prevented and the patients’ capacity to
solve problems is promoted. This intervention also led to a
higher health-related quality of life.
Surprisingly, fatigue also was a main problem in patients
who discontinued HPN. Their fatigue scores were higher
than those in patients still on HPN. This can possibly be
explained by having less energy because of their nutritional
status. To maintain their body weight, these patients have to
eat often during the day.
Importantly, we included about 70% of all Dutch HPN
patients who were treated according to largely similar
protocols. The 30% not included in this study did not differ
from our sample in gender, age, duration or indication for
HPN. Therefore, the sample seems representative of the
whole population of HPN patients in the Netherlands.
Unfortunately, reasons for not participating are unknown.
We used validated questionnaires and a strength of our
present study is that there were no missing data. With the
exception of the patients who died, there was no loss to
follow-up in 2007.
A weakness of this study, however, is that although we
included about 70% of the Dutch HPN population, the
sample size as a whole remains relatively small. Due to this
problem, we could only include the total SIP-68 score in
our analysis and not its different subscales. Based on these
notions, an additional longitudinal, and ideally a multi-
centre international study, is recommended. Several factors,
including variables of disease severity, subscales of the SIP-
68, sleep disturbance, and general and HPN-related
characteristics could be included in this study.
B SE B β p value
Model 1 Complete model
Constant 13.926 11.333 0.224
Fatigue baseline 0.653 0.106 0.659 0.000
Social companionship 0.262 0.371 0.65 0.483
Avoidance 0.537 0.309 0.149 0.087
Functional impairment 0.110 0.502 0.088 0.400
BDI −0.245 0.502 −0.053 0.627
Self-efficacy −0.704 0.394 −0.167 0.079
Final model
Constant 1.777 5.231 0.735
Fatigue baseline 0.714 0.082 0.720 0.000
Avoidance 0.597 0.298 0.165 0.049
Model 2 Complete model
Constant 50.408 10.833 0.000
Social companionship −0.158 0.425 −0.038 0.711
Avoidance 0.040 0.355 0.011 0.911
Functional impairment 0.463 0.138 0.364 0.001
BDI 1.041 0.568 0.218 0.071
Self-efficacy −1.062 0.402 −0.269 0.010
Final model
Constant 49.472 7.742 0.000
Functional impairment 0.465 0.136 0.366 0.001
BDI 1.102 0.535 0.230 0.043
Self-efficacy −1.100 0.385 −0.279 0.006
Table 4 Linear multiple regres-
sion of complete model and
final model
274 Int.J. Behav. Med. (2011) 18:268–276The importance of identifying modifiable factors to
predict fatigue is that these can help in the prevention and
treatment of this problem.
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